Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at ... Wall Street Journal Additionally, Debio 0932 also showed strong synergy with everolimus in multiple patient derived and conventional RCC cell lines. Similar synergy and anti-tumor activity with Debio 0932 in combination with these agents was also demonstrated in human ... |
